AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

Efficacy and Safety of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study (ASTRO 2025) - No abstract available

Clinical • Combination therapy • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Targeting tumor vascular endothelial cells for hepatocellular carcinoma treatment. (PubMed, World J Gastroenterol) - "Recently, Wu et al reported that apatinib, an inhibitor of vascular endothelial growth factor receptor 2, can inhibit tumor VEC glycolysis by regulating phosphatidylinositol 3-kinase/protein kinase B/6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 signaling pathway to suppress HCC progression. With great interest, this editorial paper aims to review the function and key molecular signaling pathways of tumor VECs in HCC initiation and progression and summarize potential treatment options in clinical trials."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • CD8

TASK-05: HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Oncology • Solid Tumor

Apatinib Reverses Tamoxifen Resistance in ER+ Breast Cancer via the VEGFR2/ERα/PI3K/Akt Pathway (ESMO 2025) - No abstract available

Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • KDR

Case Report: Long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy. (PubMed, Front Immunol) - "The patient received nivolumab with oxaliplatin, leucovorin, and fluorouracil plus local radiotherapy as first-line treatment; nivolumab, paclitaxel polymer micelles, and carboplatin as the second-line treatment, and nivolumab and apatinib as the third-line treatment. Genomic and immune characteristics were analyzed to understand the underlying disease mechanisms. In conclusion, integrated therapy (immunotherapy, chemotherapy, local radiotherapy, and anti-angiogenic therapy) may be the ideal treatment approach for patients with GSCC with multiple metastases; however, prospective studies are needed to verify its efficacy."

Journal • Epstein-Barr Virus Infections • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer (clinicaltrials.gov) - P2 | N=37 | Recruiting | Sponsor: Yongjun Chen

New P2 trial • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Mesenteric Artery Dissection Aneurysm Associated with Apatinib in a Prostate Cancer Patient: A Case Report and Literature Review. (PubMed, Res Rep Urol) - "As clinicians, it is imperative to remain vigilant against potential complications such as arterial dissection and aneurysm, while conducting meticulous evaluations of associated risks. Notably, this article serves solely as a reference and does not advocate for the adjustment of treatment protocols on this basis."

Journal • Cardiovascular • Gastric Cancer • Genito-urinary Cancer • Oncology • Pain • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Perioperative Camrelizumab plus Rivoceranib in Resectable Hepatocellular Carcinoma (CARES-009): A Randomized, Multicenter, Phase 3 Trial (ESMO 2025) - No abstract available

Clinical • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma. (PubMed, Afr Health Sci) - "Follow-up results showed that the Combination group had a significantly better overall survival (OS) and progression-free survival (PFS) than the Control group. Compared with temozolomide alone, apatinib plus tenozolomide can significantly improve the clinical efficacy in treating recurrent malignant brain glioma, prolong the survival of patients and produce tolerable adverse reactions."

Journal • Retrospective data • Brain Cancer • Cardiovascular • Dermatology • Glioma • High Grade Glioma • Hypertension • Oncology • Renal Disease • Solid Tumor

Effectiveness and Safety of Camrelizumab Plus Rivoceranib Combined With TACE With or Without HAIC in First-Line Treatment of Unresectable Hepatocellular Carcinoma (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

HCC-IM-1: Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Fudan University

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

Adebrelimab plus Apatinib and Etoposide in the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study (ESMO 2025) - No abstract available

P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

The tumor suppressor DACT3 sensitizes triple-negative breast cancer to apatinib by inhibiting the Wnt/β-catenin pathway. (PubMed, Transl Oncol) - "Furthermore, we explored that the exogenous expression of DACT3 could downregulate the IC50 of apatinib (Vector vs DACT3: 16.04 μM vs 8.81 μM in MDA-MB231 cells, 19.65 μM vs 9.42 μM in YCCB1 cells) by inhibiting the Wnt/β-catenin signaling, a pro-malignancy pathway that leads to apatinib resistance through crosstalk with the VEGF/VEGFR2 pathway. In summary, our results indicate that DACT3 is a potential biomarker for predicting the response to apatinib and a new therapeutic target for improving TNBC sensitivity to apatinib."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

SYSKY-2023-1016-01: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • BRCA

FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - P2 | N=716 | Recruiting | Sponsor: Fudan University | Trial completion date: Sep 2025 ➔ Sep 2028 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • FOXC1 • HER-2 • PGR

CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov) - P3 | N=572 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Oct 2026 ➔ Apr 2027 | Trial primary completion date: Apr 2026 ➔ Oct 2026

Monotherapy • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Apatinib versus Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Updated Overall Survival Results from the Phase 3 REALITY trial (ATA 2025) - No abstract available

Clinical • Metastases • P3 data • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Safety and Efficacy of Camrelizumab Combined With Apatinib for Advanced Gastric Cancer: A Systematic Review and Meta-Analysis (ACG 2025) - "564 patients from 14 studies were included in the analysis. The pooled 1-year overall survival (OS) from 8 studies was 61% (95% CI: 45–75; I² = 81.4%), with significantly higher OS of 74% (60–86; p = 0.0092; I² = 63.5%) in the treatment-naïve subgroup compared to the pretreated subgroup [45% (29–62; I² = 63.1%). The pooled 1-year progression-free survival was 22% (6–45; I² = 88.3%."

Metastases • Retrospective data • Review • Dermatology • Gastric Cancer • Leukopenia • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia

Efficacy and Safety of Camrelizumab Plus Apatinib for Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis (ACG 2025) - "The pooled 1-year overall survival (OS) from 6 studies was 71% (95% CI: 50 – 89%; I2 = 94.1%), with treatment naïve patients showing a statistically higher 1-year OS of 95% (95% CI: 90 – 98%; I2 = 0%) than 55% (95% CI: 41 – 69; p-value < 0.0001; I2 = 75.7%) in pretreated patients. 1-Year progression-free survival (PFS) was 25% (13 – 39; I2 = 72.5%) across 4 studies. Overall response rate was significantly higher in the treatment-naïve group [87% (95% CI: 80 – 93); I2 = 14%] than the previously treated group [28% (95% CI: 18 – 40); I2 = 72.5%]."

Retrospective data • Review • Anemia • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Squamous Cell Carcinoma • Thrombocytopenia

A Phase II Study of Firmonertinib Combined With Apatinib as First-Line Therapy in NSCLC Patients With EGFR Uncommon Mutations (IASLC-WCLC 2025) - "Although afatinib or osimertinib as preferred first-line therapy options have been recommended for the treatment of non-small cell lung cancer (NSCLC) with EGFR uncommon mutations, patients' therapeutic demands are far from being met. No treatment-related deaths were reported. Conclusions : Firmonertinib combined with apatinib demonstrated promising antitumor activity and a manageable safety profile for metastatic non-small cell lung cancer with EGFR uncommon mutations."

Clinical • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma. (PubMed, Clin Cancer Res) - P1 | "The combination of M1-c6v1 with camrelizumab and apatinib demonstrates an acceptable safety profile and promising efficacy in advanced HCC."

Journal • Hematological Disorders • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Influenza • Oncology • Respiratory Diseases • Solid Tumor

Clinical benefit of camrelizumab (cam) + rivoceranib (rivo) in unresectable hepatocellular carcinoma (uHCC) patients with macrovascular invasion (MVI) and extrahepatic spread (EHS), CARES-310 (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Neoadjuvant therapy of sequential transcatheter arterial chemoembolization, camrelizumab and apatinib for single large hepatocellular carcinoma (NEO-START): A randomized controlled trial (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Fuzuloparib (FZPL) monotherapy or in combination with apatinib (APA) as first-line (1L) maintenance therapy in advanced ovarian cancer (OC): final analysis of the FZOCUS-1 trial (ESMO 2025) - No abstract available

Clinical • Combination therapy • Metastases • Monotherapy • Oncology • Ovarian Cancer • Solid Tumor

Study of combination of camrelizumab and apatinib for the neoadjuvant treatment of TNBC with TILs>10% (ChiCTR) - P2 | N=58 | Recruiting | Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University

New P2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR